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Single ventricleBackground: The prevalence of single ventricle patients palliated with Fontan operation continues to grow
worldwide. This study systematically reviewed existing evidence and performed a meta-analysis to determine
the safety and efﬁcacy of endothelin receptor antagonism in single ventricle physiology with Fontan palliation.
Methods: Keyword and reference search was conducted in PubMed Cochrane Library, Web of Science, Google
Scholar, and ClinicalTrials.gov databases. Inclusion criteria were — study design: randomized controlled trials,
cohort studies, prospective studies, or retrospective studies; subjects: single ventricle patients with Fontan
palliation; main outcome: exercise or functional capacity; language: English; and article type: peer-reviewed
publications.
Results: Five studies met the inclusion criteria, including three pre–post studies, one randomized crossover open
label clinical trial, and one double-blind randomized controlled clinical trial. Study durations ranged from 3.5 to 6
months, with a total sample size of 123. Bosentan was the single endothelin receptor blocker used in all studies.
No signiﬁcant increase in liver toxicity or other serious adverse events were reported in these studies.
Meta-analysis found bosentan use to be associated with improvement in functional class (p= 0.0007); whereas
no signiﬁcant change in six-minute walk distance, resting oxygen saturation, andmaximal oxygen consumption
was identiﬁed.
Conclusions:Bosentanwas found to be a safe andwell tolerated endothelin receptor antagonist in Fontan patients
over 3–6months of therapy. Bosentan usewas associatedwith improved functional capacity. Future studieswith
larger sample size and longer duration are warranted to examine the long-term safety and efﬁcacy of endothelin
blockade in Fontan physiology.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The prevalence of single ventricle patients palliated with the Fontan
operation continues to grow worldwide [1–4]. Fontan patients' long-
term survival and exercise capacity are largely dependent upon their
pulmonary vascular resistance [5–7]. Pulmonary vascular constriction
has been linked to the surface endothelin-1 receptors on the pulmonary
vascular bed [8]. While endothelin receptor antagonists have been
shown to improve hemodynamics and exercise capacity in patients
with pulmonary arterial hypertension, [9–11] their efﬁcacy has yet
to be assessed in patients with Fontan physiology. This study systemat-
ically reviewed existing evidence and performed a meta-analysis to
determine the safety and efﬁcacy of endothelin receptor antagonism
in single ventricle physiology with Fontan palliation.ss article under the CC BY license (ht2. Methods
2.1. Study selection criteria
Studies that met the following inclusion criteria were included in
this review — study design: randomized controlled trials, cohort
studies, prospective studies, or retrospective studies; subjects: single
ventricle patients with Fontan palliation; main outcome: exercise or
functional capacity; language: English; and article type: peer-reviewed
publications. Studies that examined the effects of endothelin receptor
antagonists (ERAs) in congenital heart disease population other than
Fontan patients were excluded from the review. Case reports were
also excluded.
2.2. Search strategy
Keyword search was conducted in PubMed, Cochrane Library,
Google Scholar and ClinicalTrials.gov databases. The search algorithmtp://creativecommons.org/licenses/by/4.0/).
Fig. 1. Study selection ﬂow chart.
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three groups: (1) “bosentan”, “endothelin blockade”, or “endothelin
õantagonist”; (2) “Fontan” or “single ventricle physiology”; and
(3) “congenital”. Titles and abstracts of the articles identiﬁed through
keyword search were screened against the study selection criteria. Po-
tentially relevant articles were retrieved for evaluation of the full text.
We also conducted a reference list search (i.e., backward search) and
cited reference search (i.e., forward search) from full-text articles meet-
ing the study selection criteria. The backward/forward reference search
wasperformed inWebof Science andGoogle Scholar. No further articles
were identiﬁed through this process. The search was completed on
March 8, 2015.
2.3. Data extraction
A standardized data extraction form was used to collect the follow-
ing methodological and outcome variables from each included study:
ﬁrst author, publication year, article title, study design, sample size,
attrition rate, gender, age range, study duration, dose of ERA, Fontan
type, six-minute walk test (6MWT), resting oxygen saturation, New
York Heart Association (NYHA) functional classiﬁcation, maximal oxy-
gen consumption (VO2 max), cardiopulmonary exercise test duration,
ventricular function, cardiac output, brain natriuretic peptide (BNP)
test, drug toxicity, adverse event, quality of life, and study inclusion/
exclusion criteria.
2.4. Study quality assessment
Two reviewers independently assessed the quality of the selected
studies based on 10 dichotomous criteria that were adapted from the
National Institute of Health's tools for assessing risk of bias in random-
ized controlled trials and cohort studies [12]. The criteria include:
(1)Was the study a randomized controlled trial? (2)Were key baseline
characteristics between intervention/control groups balanced? (3)Was
the overall drop-out rate at study endpoint 20% or less of the number al-
located to treatment? (4) Did the study specify the exclusion of patients
based on use of phosphodiesterase-5 inhibitors, prostonoids, and other
pulmonary vasodilators without a sufﬁcient washout period? (5) Were
concomitant medications tracked or speciﬁed in baseline characteris-
tics? (6) Were study procedures documented in detail in the article?
(7) Was the study question or objective clearly stated? (8) Were eligi-
bility/selection criteria for the study population pre-speciﬁed and clear-
ly described? (9) Was the sample size sufﬁciently large to examine
outcomes of interest? (10) Were the outcome measures pre-speciﬁed,
clearly deﬁned, validated, and consistently assessed across study partic-
ipants? A total study quality score ranging from zero to 10was obtained
for each study by summing up these criteria. Quality score helped mea-
sure the strength of the study evidence, but was not used to determine
the inclusion of studies.
2.5. Statistical analysis
Meta-analysis was performed on 6MWT, resting oxygen saturation,
VO2 max, and NYHA functional class outcomes. Across-study heteroge-
neity was assessed using the I2 statistic, which indicates the percentage
of variability in effect estimate that is due to heterogeneity rather than
chance. We reported results from both random-effect and ﬁxed-effect
models. Paired t-test was performed using the granular functional
class data (n = 21) provided by Ovaert et al. [11], Bowater et al. [9]
and Derk et al. [10]. Ovaert et al. [11] only reported range along with
mean difference for certain outcomes. The range rule (standard devia-
tion is approximated by range divided by six) was used to calculate
the standard deviation [13]. Publication biaswas assessed by the Egger's
test [14] and the Begg's test [15]. All statistical analyses were conducted
using Stata 14.0 SE version (StataCorp, College Station, TX).3. Results
3.1. Study selection
As Fig. 1 shows, among a total of 6425 studies identiﬁed from key-
word search, 6337 of them were excluded in title and abstract screen-
ings. The remaining 88 articles were reviewed in full texts, and 83 of
them were excluded for not meeting the study design or population of
interest speciﬁed in the inclusion criteria. A backward/forward refer-
ence searchwas conducted on theﬁve selected articles, but no addition-
al article that met the inclusion criteria was found.
3.2. Basic characteristics of the included studies
Study characteristics and main ﬁndings are summarized in Tables 1
and 2, respectively. All studies are fairly recentwork published between
2009 and 2014. Study designs included three prospective pre–post
studies (Bowater et al. [9]; Derk et al. [10]; Ovaert et al. [11]), one ran-
domized crossover open label clinical trial (Schuuring et al. [16]) and
one double-blind randomized controlled clinical trial (Herbert et al.
[17]). Study durations ranged from 3.5 to 6months, with a total sample
size of 123 patients.
3.3. Intervention effectiveness
All studies found bosentan to be safe andwell tolerated in Fontan pa-
tients. No study reported a signiﬁcant increase in liver toxicity or liver en-
zyme level above three times the upper limit or normal level. No serious
adverse event was reported during the study follow-up period. Among
the three studies that examined BNP as an outcome, two of them (Derk
et al. [10]; Schuuring et al. [16]) found no signiﬁcant change in BNP levels
and one (Herbert et al. [17]) reported a signiﬁcant decrease in BNP levels
(−1.9 ng/L; 95% conﬁdence interval [CI] = −4.9 ng/L, −0.5 ng/L;
p= 0.028) for the bosentan treatment group. Herbert el al. [17] reported
a small but signiﬁcant decrease in hemoglobin levels (−0.3mmol/L; 95%
CI =−0.5 mmol/L,−0.1 mmol/L; p = 0.0001).
In meta-analysis on 6MWT distance, I2 statistics equals 65.5% (p =
0.055). There is some discrepancy regarding the estimated effect of
bosentan treatment on 6MWT distance between random-effect and
ﬁxed-effect models. The estimated pooled effect size in the random-
effect model is 19.765 m (95% CI = −26.982 m, 66.512 m; p =
0.407), whereas that in the ﬁxed-effect model is 23.146 m (95% CI =
Table 1
Characteristics of included studies.
ID First author Publication year Country Initial sample size Effective sample size Attrition rate Age range (years) Gender (M/F)
1 Ovaert 2009 Belgium 10 9 10% 4.4–33 7/3
2 Bowater 2012 United Kingdom 8 6 25% 25.2–39.9 3/3
3 Schuuring 2013 Amsterdam 42
Treatment: 21
Placebo: 21
32
Treatment: 32
Placebo: 16
24% 18–55 Treatment: 11/10
Placebo: 11/10
4 Derk 2014 USA 10 7 30% 18–47 3/7
5 Herbert 2014 Denmark 75
Treatment: 36
Placebo: 39
69
Treatment: 32
Placebo: 37
8% 13–28 Treatment: 21/15
Placebo: 24/15
ID First author Setting Study design Treatment duration
(months)
Bosentan dosage Fontan
1 Ovaert Multicenter Prospective single arm 4 62.5 mg BID for 1st month, 125 mg
BID for 3 months
3 extracardiac; 7 intracardiac
2 Bowater Single center Prospective single arm 6 62.5 mg BID for 2 weeks, then titrated
up to 125 mg BID for 3 months
5 RA:PA; 1 TCPC
3 Schuuring Multicenter Randomized crossover
clinical trial, open label
6 125 mg BID Treatment:
20 RA:PA; 4 intracardiac; 18 extracardiac
Placebo:
11 RA:PA; 2 intracardiac; 8 extracardiac
4 Derk Single center Prospective single arm 4 62.5 mg BID for 1st month, 125 mg
BID for 3 months
5 RA:PA; 1 intracardiac;
3 extracardiac; 1 LA:PA (fenestrated)
5 Herbert Multicenter Double-blind randomized
clinical trial
3.5 62.5 mg BID for 2 weeks, then titrated
up to 125 mg BID for 3 months
Treatment:
4 RA:PA; 23 intracardiac; 9 extracardiac;
Placebo:
2 RA:PA; 22 intracardiac; 15 extracardiac;
ID First
author
Adverse event# (%) Study inclusion criterion Study exclusion criterion
1 Ovaert 2 (20) transient fatigue, 1(10) weight gain and
edema (discontinued), 2 (20) mild upper airway
infection, 1(10) fever due to herpes reactivation
Fontan patients; 2 years or older; heart failure at
least 6 months after the Fontan operation; oxygen
saturation below 90% at rest or exercise; low
output with elevated venous pressure;
protein-losing enteropathy; 2,3,4 functional class
Treatable causes of heart failure; pregnant; systolic
blood pressure below 80% of normal range; levels of
aspartate aminotransferase or alanine
aminotransferase 3 times the upper limit of normal;
moderate to severe liver disease; hemoglobin or
hematocrit below 75% of normal, use of pulmonary
vasodilators
2 Bowater 3 (38) reported headache which resolved at 1
month follow-up, 1 (13) leg edema which resolved
within ﬁrst month, 1 (13) thyrotoxicosis
secondary to amiodarone therapy (discontinued)
Fontan patients; 18 years or older; NYHA greater
than or equal to 2
Lack of sinus rhythm; hematological abnormality;
renal dysfunction; pre-existing liver disease;
treatment with prostanoids, ERAs,
phosphodiesterase type-5 inhibitors within 1 month
of study enrollment
3 Schuuring Treatment group: 3 (7) headache, 1 (2) dyspnea
on exertion, 1 (2) peripheral edema, 1 (2) anemia
and leukopenia
Fontan patients Subpulmonary ventricle; moderate or severe liver
disease; use of cyclosporine A; pregnancy
4 Derk 1 (10) chest pain (discontinued), 1 (10)
palpitations (discontinued), 3 (30) fatigue
(discontinued)
Fontan patients; 12 years or older Pregnancy; use of cyclosporine; levels of aspartate
aminotransferase or alanine aminotransferase 3
times the upper limit of normal; contraindications
to MRI; use of phosphodiesterase-5 inhibitors or
other pulmonary vasodilators
5 Herbert Treatment group: 1 (3) chest pain (discontinued),
1 (3) recurrence of protein-losing enteropathy
(discontinued); 1(3) inﬂuenza (discontinued); 6
(17) ﬂushing
Placebo group: 1(3) recurrence of protein-losing
enteropathy (discontinued), 1 (3) ﬂushing
Fontan patients; 12 years or older; clinically stable
(no change 3 months prior);
NYHA class IV; systolic blood pressure below 80% of
normal range; oxygen saturation below 85%;
neurological sequelae; liver or renal impairment;
patients on pulmonary vasodilators
Notes: RA: right atrium, LA: left atrium, PA: pulmonary artery, TCPC: total cavopulmonary connection.
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estimate because I2 statistic is greater than 50%, the conventional
range for substantial across-study heterogeneity.
Bosentan treatment did not demonstrate any signiﬁcant effect on rest-
ing oxygen saturation. The I2 statistics inmeta-analysis equals 44.3% (p=
0.166). The estimated pooled effect size in the ﬁxed-effect model is
−0.448% (95% CI = −2.113%, 1.216%; p = 0.598), and that in the
random-effect model is 0.633% (95% CI =−2.52%, 3.786%; p = 0.694).
No signiﬁcant effect on VO2 max was found for bosentan treatment.
The I2 statistics in meta-analysis equals 22.5% (p= 0.276). The estimat-
ed pooled effect size in the ﬁxed-effect model is−0.643ml/kg/min (95%
CI =−0.272 ml/kg/min, 1.559 ml/kg/min; p = 0.168), and that in therandom-effect model is 0.502 ml/kg/min (95% CI =−0.680 ml/kg/min,
1.684 ml/kg/min; p = 0.405).
Two out of the ﬁve studies (Bowater et al. [9]; Herbert et al. [17])
found bosentan treatment to be associated with signiﬁcant improve-
ment in functional class. Paired t-test using the combined granular func-
tional class data (n = 21) from the other three studies (Bowater et al.
[9]; Derk et al. [10]; Ovaert et al. [11]) estimates the mean change in
functional class to be 0.523 improvement (95% CI = 0.392, 0.654; p =
0.0007) following bosentan treatment.
Neither the Egger's test nor the Begg's test is statistically signiﬁcant,
indicating the absence of publication bias or lack of statistical power to
detect such bias.
Table 2
Summary of study ﬁndings.
ID First author 6MWT distance
(mean difference ± SE)
Resting oxygen saturation
(mean difference ± SE)
NYHA functional class VO2 max from stress test
(mean difference ± SE)
1 Ovaert (−35.5 m± 30.368 m)
95% CI [−95.02, 24.02];
p = 0.27
(+3.0% points ± 2.61% points)
95% CI [−2.2, 8.2]; p = 0.16
4 improved 1 functional class, 5 unchanged; p = NS (−0.05 ml/min/kg ± 1.512 ml/min/kg)
95% CI [−3.01, 2.91]; p = 0.9747
2 Bowater (+25 m± 9 m)
95% CI [7.36, 42.64];
p = 0.07
(−1.2% points ± 0.937% points)
95% [−3.04, 0.64]; p = 0.5827
5 improved 1 functional class; 4 improved from 2 to 1,
1 improved from 3 to 2, 1 remained at 2; p = 0.04
(−0.4 ml/min/kg ± 5.174 ml/min/kg)
95% CI [−9.74, 10.54]; p = 0.9409
3 Schuuring NA NA Treatment group: 6 improved, 24 unchanged, 2 declined;
placebo group: 15 unchanged, 1 declined; p = NS
(−0.6 mL/kg/min ± 0.85 mL/kg/min)
95% CI [−2.3, 1.2]; p = 0.63
4 Derk (+73 m± 35 m)
95% CI [4.40, 141.60];
p = 0.03
(+3% points ± 3.14% points)
95% CI [−3.15, 9.15]; p = 0.18
3 improved, 3 unchanged, 1 declined; p = NS NA
5 Herbert NA NA Treatment group: 9 improved 1 FC and none deteriorated;
placebo group: 0 improved, 1 declined; ODDS ratio: 0.069;
95% CI [0.0, 0.41]; p = 0.0085
(+1.39 mL/kg/min ± 0.606 mL/kg/min)
95% CI [0.18, 2.59]; p = 0.0245
ID First
author
Cardiopulmonary
exercise test duration
Ventricular function Cardiac output BNP Toxicity
1 Ovaert Reported for one patient:
improved from 3 to 8min
NA NA NA NA
2 Bowater NA Signiﬁcant increase in ventricular
systolic annular velocity
by 1.8 ± 2.1; p = 0.009
NA NA No signiﬁcant difference in AST,
creatinine, potassium, hemoglobin,
platelet count levels
3 Schuuring NA NA (+0.2 L/min) 95% CI
[−0.3, 0.8] p = 0.46
(−13 ng/L) 95% CI [284, 259];
p = 0.19
No signiﬁcant difference in creatinine,
albumin, sodium, and hemoglobin
4 Derk NA Signiﬁcant increase inMRI-derived
cardiac output 7.1 L/min ±
2.8 L/min;
p = 0.04
+1.1 L/min ± 0.23 L/min,
p = 0.03
(+6.72 ng/L) 95% CI
[−32.642, 19.202]; p = 0.61
No signiﬁcant difference in AST, ALT,
total bilirubin
5 Herbert +0.39 min; 95% CI
[0.01, 0.77];
p = 0.042
NA NA −1.9 ng/L; 95% CI
[−4.9,−0.5];
p = 0.028
No signiﬁcant hepatotoxicity.
Signiﬁcant decrease in hemoglobin
−0.3; 95% CI [−0.5,−0.1];
p = 0.0001
Notes: NA: test not done or not reported, NS: not signiﬁcant (actual value not reported), SE: standard error. The range rule was used to calculate the standard deviation if not reported:
range/6 = standard deviation.
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Table 3 reports results from the study quality assessment. Studies in-
cluded in the review on averagemet seven out of 10 quality criteria, but
the distribution of qualiﬁcation differed substantially across criteria.
Only two studies had balanced key baseline characteristics between in-
tervention/control groups and an overall drop-out rate of 20% or less;
whereas all articles documented study procedures in detail, clearly stat-
ed study hypothesis or objective, and pre-speciﬁed eligibility/selection
criteria for the population under investigation.Table 3
Study quality assessment.
Criterion Proportion of
studies that
meet criterion (%)
Was the study a randomized controlled trial? 2/5 (40%)
Were key baseline characteristics between
intervention/control groups balanced?
1/5 (20%)
Was the overall drop-out rate at study endpoint 20% or less of
the number allocated to treatment?
2/5 (40%)
Did the study specify the exclusion of patients based on
phosphodiesterase-5 inhibitors, prostonoids, and other
pulmonary vasodilators?
4/5 (80%)
Were concomitant medications tracked or speciﬁed in
baseline characteristics?
4/5 (80%)
Were study procedures documented in detail in the article? 5/5 (100%)
Was the study question or objective clearly stated? 5/5 (100%)
Were eligibility/selection criteria for the study population
pre-speciﬁed and clearly described?
5/5 (100%)
Was the sample size sufﬁciently large to examine outcomes of
interest?
2/5 (40%)
Were the outcome measures pre-speciﬁed, clearly deﬁned,
validated, and consistently assessed across study
participants?
5/5 (100%)4. Discussion
Evidence from this systematic review and meta-analysis suggests
that bosentan is safe and well tolerated in patients with Fontan circula-
tion. Fontan patients are at increased risk for liver disease due to chronic
venous congestion and low cardiac output [19,20]. No study included in
this review found signiﬁcant increase in liver enzyme level or liver tox-
icity over 3 to 6 months of bosentan therapy. Moreover, bosentan use
was found to be signiﬁcantly improves Fontan patients' functional ca-
pacity. However, the long-term safety and tolerability of bosentan and
other endothelin blockers, especially regarding liver toxicity, still
warrant investigation. Herbert el al. [18] reported a small but signiﬁcant
decrease in hemoglobin levels, which is a known side-effect of bosentan.
Evidence regarding the effect of bosentan use on improvement in
six-minute walk distance is inconclusive. The ﬁxed-effect but not the
random-effect estimate (which is preferred) found a statistically signif-
icant increase in this outcome measure. It is also important to note the
substantial variability of 6MWTs as a measure for submaximal exercise
capacity. The number of 6MWTs a patient performs tends to bepositively associated with his or her six-minute walk distance, with
the largest increase in distance observed during the ﬁrst three trials
[20]. It is thus recommended to perform at least two 6MWTs for each
data point with results compared. If the between-test variations are
less than 10%, the test may be considered a valid measure for a patient's
functional capacity [19]. However, none of the studies included in this
review assessed or reported the between-test variability of the 6MWT.
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measures like VO2max and resting oxygen saturation, bosentan therapy
appears to show clinically signiﬁcant results in some Fontan patients
[9–11,17]. The challenge remains to identify characteristics that may
predict which patients beneﬁt more (or less) from bosentan therapy.
5. Limitations
A few limitations in the reviewed studies should be noted. Most
studies had small sample size, which is common for research on
congenital heart disease populations. Attrition rate was higher than
20% for three of the ﬁve studies included in the review, which may
compromise treatment effect estimation. Studies in the review varied
substantially by their primary outcome measures, making meaningful
comparisons difﬁcult or infeasible. Granular data was available for
only a limited number of studies and outcomes, so that additional
assumptions on thedata distribution had to bemade in order to conduct
meta-analysis.
6. Conclusion
Bosentanwas found to be a safe andwell tolerated endothelin recep-
tor antagonist in Fontan patients over 3 to 6 months of therapy.
Bosentan use was associated with improved functional capacity. Future
studies with larger sample size and longer duration are warranted to
examine the long-term safety and efﬁcacy of endothelin blockade in
Fontan physiology.
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